号外!号外! 最新消息公布! 世界最权威的《科学杂志》最近盘点了2023年全球最重大的科学成果。GLP-1居然排名第一,成為Science科学杂志的封面故事! Three国际公司首席科学家丹博士今年9月公布的公司四个植物营养素产品对人体8个重要基因的具有积极调节作用的研究成果中就包括GLP-1。 这说明Three公司在这方面的科学研究及其应用技术走在了同行业的最前列! GLP-1激动剂药物以其在医学和文化領域的革命性突破被评为今年焦点的理由是广泛的。除了帮助治疗无数糖尿病患者、数百万人減轻体重外,最新研究表明這些药物可能对心力衰竭和肾病等疾病产生引人注目的益处。 如何开发自身GLP1的水平,也許是未来主动式健康应該关注的目标之一。 Three国际公司的Revive和Vitalite可以通过表观遗传学的方式对GLP1基因進行正向调节(分別為348%和293%的提升)。Three国际公司作為一個細胞吸收技術公司在天然有机植物營養素領域,显然已經走在了世界的最前沿,引领着行业的新方向。 12/17/2023@旧金山北湾 The Science magazine highlighted GLP-1 agonists as the most significant breakthrough of 2023, recognizing their revolutionary impact in the medical and cultural fields. These drugs, known for treating numerous diabetes patients and aiding millions in weight loss, have recently shown notable benefits for conditions such as heart failure and kidney disease. The development of strategies to enhance endogenous GLP-1 levels might become a key focus for proactive wellness in the future. Based on most recent epigenetic research study, Drs. Catherine Davis and Paul Davis have found “Revive” and “Vitalite” can positively regulate the GLP-1 gene, resulting in a remarkable increase of 348% and 293%, respectively. As a cellular absorption technology company in the field of natural organic phytonutrient supplements, THREE International appears to be the first company at the forefront globally, leading the industry in a new direction. 12/17/2023 @ North Bay, San Francisco.